Background Breakthrough cancer pain (BTcP) is one of the most common symptoms related to the disease and its treatment. Its management differs from that of chronic pain but there is not a wide consensus about fundamental aspects of BTcP definition, diagnosis, follow-up, and management. The objective of this study is to reach a consensus on the follow-up of patients with BTcP under opioid treatment. Background This work was conducted using a modified Delphi method organized in two rounds and involving a panel of 84 medical oncologists. A questionnaire of 66 items was developed with the following topics: (1) When to perform the first and subsequent BTcP treatment evaluations; (2) What to assess at the first follow-up visit and how; and (3) What to assess in the following visits and how. Results After two rounds, a consensus was reached in 53 of 66 items proposed (80.3%). The main agreements reached include: The first follow-up visit should preferably be face-to-face; increase the number of visits after detecting poor control of BTcP; assess pain control episodes of BTcP in the first and following visits; adjust treatment dose of opioids due to poor control of BTcP; and adopt measures to prevent aberrant opioid-induced behaviors when treating BTcP in patients with cancer. Conclusion This Delphi consensus highlights the different points of view of medical oncologists regarding the follow-up of patients with BTcP under opioids treatment. Nonetheless, the conclusions reached can facilitate optimizing monitoring of these patients and promote long-term effectiveness of BTcP control.
Introduction
Cancer patients must deal with pain, one of the most common symptoms related to the disease and its treatment. The prevalence of pain in these patients ranges from 39.3% after curative treatment, 55.0% during anticancer treatment, and 66.4% in advanced, metastatic, or terminal disease [1] . Cancer pain can be classified in terms of its intensity (mild, moderate, or intense), duration (acute or chronic), and physiopathology (nociceptive, neuropathic, or mixed) [2] . Patients with cancer-related chronic pain usually experience fluctuations in pain intensity that occur as discrete transient pain flares. When these flares interrupt a tolerable background pain, they are commonly described as breakthrough pain [3] .
Although there is no commonly agreed definition of breakthrough cancer pain (BTcP), the most widely accepted is "a transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain" [4] . Patients suffering from BTcP have decreased functional capacity and increased risk of depression and anxiety. This pain has an important social cost, since it affects productivity, and also has a great impact on the quality of life of patients and their caregivers [5] . The diagnostic algorithm for BTcP proposed by Davies is widely used in clinical practice [4, 6] , and there are also two assessment tools to discriminate BTcP from uncontrolled background pain, such as the breakthrough pain assessment tool (BAT) and the Alberta Breakthrough Pain Assessment Tool (ABPAT) [7, 8] . The objective of the treatment of BTcP is to minimize the intensity and severity of each pain episode, and to reduce its impact on patients' quality of life.
Opioids represent the cornerstone of treatment for acute and chronic pain, including BTcP [9] . However, the characteristics of BTcP make its management different from chronic pain. The slow onset of action of opioids (20-30 min, reaching a peak of analgesia in 60-90 min) results in delayed or ineffective analgesia, while the prolonged duration of effect (3-6 h) results in ongoing adverse events [10] . A metaanalysis concluded that the efficacy of rapid-onset opioids (such as fentanyl) is superior to oral morphine in control of BTcP [11] . The European Society for Medical Oncology (ESMO) and the Spanish Society of Clinical Oncology (SEOM) recommend the use of transmucosal fentanyl to treat BTcP [2, 6] .
Because pain may change as the disease and treatment progress, it is necessary to follow the patient from the beginning, not only at the time of drug titration [12] . In addition, despite the efficacy of opioids in cancer patients, recent publications have stated that there are concerns about their inappropriate use, with aberrant opioid-induced behaviors from about 8-19% in patients taking rapid-onset opioids or traditional short-acting oral opioid for BTcP [13, 14] . Some measures adopted in order to prevent this misuse include increase awareness for early detection of risk factors (addictive personality or psychiatric illness), select the appropriate rescue drug for BTcP when risk factors are detected, recruit relatives to oversee patient at home, avoid prescribing rapid-onset opioids off-license, and monitor patients regularly [14] .
The aim of this study is to gather the opinion of a panel of Spanish experts about the follow-up of patients in whom treatment for BTcP has been prescribed, and to reach a consensus using a modified Delphi method.
Methods

Study Design
This study was performed according to a modified Delphi method with the aim of reaching a consensus on the followup of patients with BTcP under opioid treatment. The process was developed in 4 stages: (1) constitution of the scientific committee in charge of the project; (2) a face-to-face start-up meeting to raise the main topics; (3) two successive rounds of online surveys to gather the opinion of a panel of experts; and (4) result analysis and conclusions discussion by the scientific committee in a face-to-face meeting. The study was approved by the Clinical Research Ethics Committee of the Hospital Clínico San Carlos (Madrid, Spain).
Participants
Three groups were involved in the study: scientific committee, assistance team, and expert panel. The scientific committee coordinated the entire consensus and developed the questionnaire, and was made up of six medical oncologists with more than 3 years of clinical experience in the treatment of patients with cancer and BTcP. The Research Unit of Luzan 5 was the assistance team, which was responsible for the distribution and analysis of the questionnaires. The expert panel was selected by the scientific committee and included 84 medical oncologists with experience in cancer pain. They were responsible for answering the questionnaire.
Questionnaire
In the face-to-face start-up meeting, the scientific committee discussed the main monitoring strategies during the period of maintenance of patients receiving treatment for BTcP according to the clinical experience of each expert, taking into account the individual characteristics of patients (fragility, age, comorbidities, treatment received, drug interactions, etc.). As a result of this meeting, it was agreed a questionnaire of 66 items in Spanish grouped in the following topics: (1) When to perform the first and subsequent BTcP treatment evaluations (11 items); (2) What to assess at the first follow-up visit and how (17 items); and (3) What to assess in the following visits and how (38 items).
A unique 9-point ordinal Likert-type scale was proposed to answer the items (minimum 1, full disagreement; and maximum 9, full agreement) [15] . This scale was structured in three groups according to the level of agreement-disagreement of the item: from 1 to 3, interpreted as disagreement; from 4 to 6, interpreted as neither agreement nor disagreement; and from 7 to 9, interpreted as agreement.
The Delphi Rounds and Consensus Meeting
The Delphi study was conducted over two rounds held between May and June 2018. In the 1st round, expert panelists answered the questionnaire via online offering the possibility of adding their opinion in open text. In the 2nd round, panelists contrasted their personal opinion with that of the other participants and, if necessary, reconsidered their initial opinion on those items where consensus was not reached at 1st round. The results of round 2 were tabulated and presented descriptively. The project was closed on September 2018 with a faceto-face meeting of the scientific committee to debate and interpret the results.
Analysis and Interpretation of Results from the Questionnaires
The final opinion on each of the items was studied through the score and the level of consensus reached by panelists. The same criteria were followed for each of the items. No consensus was reached when the scores of a third or more of panelists were in the 1-3 range, and another third or more in the 7-9 range. On the other hand, there was consensus when less than a third of the responders scored outside the 3-point range (1-3, 4-6, or 7-9) containing the median. The type of consensus achieved on each item was determined by the median value of the score. There was an agreement if the median was ≥ 7, and there was disagreement if the median was ≤ 3. When the median score was located between a 4-6 range, the items were uncertain for a representative majority of the group. A clearer consensus was reached when the score of an item was closer to 1 or 9, either in disagreement or agreement, respectively.
Results
Of the 84 experts consulted, 82 completed the two rounds of the Delphi consensus without proposing new items. In round 1, consensus was reached in 42 of 66 items; all in agreement. Twenty-four items were returned for reconsideration in round 2 and consensus was reached in 11 items; 9 in agreement and 2 in disagreement. After two rounds, a consensus was reached in 53 items (80.3%); 51 in agreement (77.3%) and 2 in disagreement (3.0%). The remaining 13 items (19.7%) did not show agreement or disagreement. Figure 1 depicts the results of the two rounds and Tables 1 and 2 show the global results for all items analyzed.
Topic 1: When to Perform the First and Subsequent BTcP Treatment Evaluations
Panelists agreed most of the items proposed about when to perform the first and subsequent BTcP treatment evaluations (items 1-11) ( Table 1) . Almost all experts agreed that more frequent visits should be done after detecting poor control of BTcP (98.82% of panelists scored in the 7-9 range). Other items with a wide agreement include considering the first follow-up visit 48-72 h after the start of BTcP treatment (88.24% of panelists agreed) and using telephone follow-up of patients with BTcP when resources are available (85.88% of panelists agreed). However, experts did not show agreement or disagreement to carry out the first follow-up visit by telephone (56.46% of panelists agreed), or to consider more frequent visits in patients with impaired liver function (56.47% of panelists agreed).
Topic 2: What to Assess at the First Follow-up Visit and how
All items related to what to assess at the first follow-up visit (items 12-18) reached consensus in most of panelists, such as the number of BTcP episodes per day (98.82% of panelists scored in the 7-9 range), the need to adjust doses due to poor control of BTcP (98.83% of panelists agreed), or the control of pain episodes (97.65% of panelists agreed) ( Table 1) .
Regarding the items related to what adverse events should be considered in the first follow-up visit of patients under treatment for BTcP (items 19-28), panelists only considered taking into account constipation, nausea, mental confusion, dizziness, and delirium (> 70% of panelists agreed). On the other hand, all experts disagreed to consider immunosuppression at the first follow-up visit. Pruritus, dyspnea, urinary retention, or diaphoresis did not achieve consensus (Table 1 ).
Topic 3: What to Assess in the Following Visits and how
This topic includes several groups of items that could be explained separately (Table 2 ). Most panelists agreed that the use of validated scales, either by the patient (selfassessment) or by the health professional (Visual Analog Scale [VAS]), will help in assessing the degree of control of BTcP and stablishing the most appropriate treatment (items 29 and 30; > 84% of panelists scored in the 7-9 range). Experts did not achieve consensus to consider the use of specific scales for the assessing of BTcP during the follow-up, such as the ABPAT (item 31).
A great proportion of panelists agreed that several adverse events may affect the control of BTcP and must be identified during the follow-up visits (items 32-39). These adverse events include liver failure, renal failure, mucositis, xerostomia, bone events, depression, and the evolution of cancer (progression or response) (> 68% of panelists agreed). However, fever did not get enough level of agreement to achieve consensus.
Most panelists agreed that concomitant treatments recently introduced for the treatment of BTcP should be evaluated (item 40; 92.94% of panelists agreed), including the appearance of possible interactions in order to optimize the treatment of BTcP (item 41; 95.30% of panelists agreed).
All items related to what to assess in the follow-up visits reached consensus (items 42-47). Panelists agreed to assess the number of BTcP episodes per day, the characteristics of BTcP, the pain control, the need to repeat doses due to poor control of BTcP, the adherence to pain treatment, and how the patient controls the appearance of pain episodes (> 92% of panelists agreed).
As with the items about the first follow-up visit, panelists did not agree which adverse events must be taken into account during the follow-up visits (items 48-58). Only constipation, nausea, mental confusion, and dizziness were agreed by more than 67% of panelists. In the same way, immunosuppression was disagreed by 98.82% of experts as the most important adverse event to take into account in the management of patients with BTcP. Pruritus, dyspnea, urinary retention, delirium, or diaphoresis did not achieve consensus.
Regarding the use of opioids for the treatment of BTcP (items 58-66), all items proposed reached consensus in agreement. Panelists agreed that the dose of opioids should be increased when the patient has 4 or more episodes of BTcP per day (> 78% of panelists agreed) or when an end-of-dose failure is identified (69.42% of panelists agreed). On the other hand, they agreed that the dose of opioids should be reduced if serious adverse events occur during BTcP treatment (75.30% of panelists agreed). In addition, they considered that it is necessary to change between different pharmaceutical forms of opioids in case of poor tolerance to the treatment (89.41% of panelists agreed) or inefficiency of the therapy (78.83% of panelists agreed). Most of the experts agreed that adjuvant 
Discussion
In general, the opinion of the participating experts on the follow-up of patients with BTcP under opioid treatment was 60. When an end-of-dose failure is identified, the dose of basal opioid treatment must be increased (An end-of-dose failure is one that occurs before or around the time prescribed for analgesia. This failure is more gradual in onset and longer in duration than the previous ones. It is usually the result of an inadequate analgesic dose or a prolonged administration interval). ABPAT, Alberta Breakthrough Pain Assessment Tool; BTcP, breakthrough cancer pain; IQR, interquartile range; VAS, Visual Analog Scale largely uniform, as suggested by the high degree of consensus reached in more than 80% of the items proposed. Two previous Spanish Delphi consensus ascertain the level of agreement among cancer pain specialists with the optimal definition, diagnosis, and management of BTcP, including a little section about BTcP follow-up [16, 17] . The experts surveyed agreed that patients and adverse events should be assessed after starting BTcP medication within 48-72 h [17] . In addition, experts recommended that the first contact with the patient (including by telephone) should be performed within the first 48 h following the initiation/titration period, and follow-up of patients should be done simultaneously to the scheduled visits and/or whenever requested by the patient [16] . Our panelists also agreed that the first follow-up visit should be done at 48-72 h after starting BTcP treatment, and should coincide with regular medical visits. However, they considered that the first follow-up visit should preferably be face-to-face, using telephone only when BTcP is well controlled or when patients have problems to attend the consultation.
The most agreed items in our study include increase the number of visits after detecting poor control of BTcP, adjust treatment dose due to poor control of BTcP, and assess pain control episodes of BTcP in the first and following visits. All these items have in common the control of BTcP. Some guidelines suggest that the occurrence of 3 to 4 BTcP episodes per day is an acceptable outcome if pain is controlled during the rest of the day [3, 4, 18] . However, this broad generalization deserves reconsideration due to the heterogeneity of BTcP [19, 20] . For example, many BTcP episodes caused by bone metastases may occur more or less frequently depending on the patient's level of activity [20] .
There are several questionnaires and patient-related instruments to assess pain control [7, 8] . However, our panelists prefer to use VAS [21] . They argued that although specific scales such as ABPAT are useful for assessing the patient during follow-up, they are not used frequently in their clinical practice and require more time to be carried out than VAS.
Our panelists agreed that more frequent visits are needed in patients with impaired renal function but not with impaired liver function. This discrepancy may be due to metabolism of opioids [22] [23] [24] . In fact, the European Palliative Care Research Collaborative opioid guidelines project only recommends fentanyl in the first-line and alfentanil in the secondline in patients with an estimated glomerular filtration rate (eGFR) < 30 ml/min [23] . In the same way, the European Association for Palliative Care (EAPC) recommends lower doses of fentanyl, buprenorphine, or methadone in these patients [24] . These strict recommendations may have led our panelists to choose renal impairment and not hepatic impairment as a factor to be considered in order to increase the number of visits to patients with BTcP.
Panelists of our study did not agree that all proposed adverse events must be considered during the first and following visits. According to the summary of product characteristics (SmPC) of opioids, some adverse events are common, such as nausea and dyspnea, but others such as pruritus are rare [25] . However, panelists considered that many of such adverse events could be due more to the cancer disease than to the treatment. Before modifying analgesic treatment as a consequence of an adverse event, they argued that other causes different from treatment must be ruled out previously. Moreover, although it is known the potential of opioids to suppress the immune response and thereby to increase the vulnerability for infections [26] , almost all panelists disagreed and argued that such adverse event is not common in their clinical practice or emerged as a consequence of chemotherapy.
According to rapid-onset opioids SmPC, dose should be adjusted if patients consistently present more than four BTcP episodes per day [25] . However, our panelists agreed that opioid doses should be increased when the patient has 4 episodes or more. They consider that patients' reports of pain episodes are not precise.
Panelists of our study agreed that consideration should be given to possible opioid abuse behaviors. However, although a stricter control measure of opioids might result in the prevention of misuse, barriers in the use of these drugs may drive to a lower use and a poor control of pain. In fact, there are large disparities in the use of opioids to control BTcP in Europe and worldwide [27] . These disparities may be due to affordability of the drug in each country or even the control measures established by the national legislations and regulations of countries [28] . This highlights the need to take adequate measures to prevent aberrant opioid-induced behaviors when treating BTcP in patients with cancer.
The limitations of this study are the same that those of studies with similar design. To minimize the influence of the promotor of consensus exercise, sponsors were not involved in the study. It is important to note that the conclusions of the study are subjective and must be taken with caution to be extrapolated to the clinical practice.
This modified Delphi procedure successfully reached consensus from a panel of medical oncologists in the management of patients with BTcP. Based on their opinions and experience, the main recommendations extracted from the results included: In conclusion, this Delphi consensus is of particular relevance, and highlights the different points of view of medical oncologists regarding the follow-up of patients with BTcP under opioid treatment. Nonetheless, the conclusions reached can facilitate the optimization of the monitoring of these patients and promote long-term effectiveness of BTcP control.
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